Sanguine Corporation Adds to its Management Advisory Team
6:00 AM ET - BusinessWire

Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce the selection of Gary L. Corderman to the Company's Management Advisory team. Mr. Corderman has over 20 years of investment experience. Corderman joined Halbert, Hargrove/Russell LLC, located in Long Beach, California in 1998. He has built his practice and service team with a focus on working with both institutional sized family/trust accounts (many of which are multi-generational) and other investment accounts that have a fiduciary nature, such as pension plans and endowment or foundation relationships.

Previously Mr. Corderman worked extensively with consulting and marketing teams that focused on both institutional as well as individual accounts. He spent time most recently with Lord Abbett Mutual Funds but also Watson Wyatt Consulting and Fidelity Investments Institutional. His duties have included a broad range of responsibilities from working directly on individual and institutional client relationships to public speaking engagements. He was also responsible for instructing and educating brokers and account executives at brokerage firms about structuring portfolios for institutional clients. Mr. Corderman received his Bachelor's degree in Business Management from Miami University and his Master of Business Administration from the Fuqua School of Business at Duke University.

Dr. Thomas C. Drees, Ph.D., CEO, added, "We continue to build our management team with talent in the areas of finance, investment and healthcare. As we continue to execute our strategy of building a company focused on long-term growth opportunities, we look toward Gary as becoming an integral part of our ability to garner Institutional support. We expect Gary's experience will aid significantly with our previously announced acquisition strategies."

About Sanguine

Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2 that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation

For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net
Recent Market News
May 2, 2008

Sanguine Corporation Receives Update from PHER-O2 Manufacturer
6:00 AM ET - BusinessWire

Sanguine Corporation (OTC Bulletin Board: SGNC) is pleased to announce that a meeting was held at the office in West Chester, Pennsylvania, with the Company's GMP pharmaceutical manufacturer of PHER-O2 to discuss the product's progress and stage of development. With the recent supply of PHER-O2 to a European medical research group for intravenous development and evaluation, Sanguine management elected to discuss the progress of PHER-O2's master drug file, improved manufacturing and requirements necessary for long term supply of product. The details of the meeting were confidential, however both companies' management were quite pleased with the progress and future of PHER-O2 as a transport medium for transplantable materials.

According to Sanguine's spokesperson, Mr. Frank Marra, "The manufacturer is one of Europe's most respected pharmaceutical groups with medical device expertise in the areas of bedside and ambulatory infusion technology, infusion disposables, enteral application technology, auto-transfusions, blood collection and processing. With the intravenous pre-clinical evaluation progressing well, and with the company's readiness to complete the master drug file necessary for a 510(k) device application, it was important to meet with our product manufacturer to discuss ways to expedite avenues to product sales. We expect PHER-O2 to be an integral part of the Company's future, once the 510(k) approval is complete."

About Sanguine

Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on the development of an oxygen-carrying synthetic substitute for human red blood cells and various other areas requiring oxygen profusion. The company is developing a synthetic red blood cell product, PHER-O2, that consists of perfluoro-decalin molecules, purified water, and a proprietary synthetic - patent pending fluorinated surfactant to hold the emulsion together.

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation

For Sanguine Corporation Michael Dancy, 801-746-3570 (Investor Relations) medancy@allwest.net

PASADENA, Calif., Jan 30, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC - News) is pleased to announce that it will be opening an
office in West Chester, Pennsylvania, to expand its operations and to secure
east coast representation. The West Chester office will house Sanguine's newly
formed life sciences division. The focus of the life sciences division is to
advance SGNC through the development and acquisition of projects and
technologies that will produce revenue for the Company. The West Chester office
will also be increasing the current efforts to commercialize Sanguine's flagship
product, PHER-02.

West Chester is located just outside of Philadelphia, Pennsylvania, an hour from
Baltimore Maryland and an hour and a half from New York City and Washington D.C.
This ideal location is going to give Sanguine much easier access to some of the
largest cities, hospitals and universities in the country.

David Nelson, Sanguine's CFO, said, "The opening of this new office is an
integral component in our strategy to advance Sanguine. We anticipate many good
things coming from this satellite office."

About Sanguine

Sanguine Corporation, a development stage bio-pharmaceutical company, focuses on
the development of an oxygen-carrying synthetic substitute for human red blood
cells and various other areas requiring oxygen profusion. The company is
developing a synthetic red blood cell product, PHER-O2 that consists of
perfluoro-decalin molecules or synthetic red blood cells, purified water, and a
synthetic and fluorinated surfactant to hold the emulsion together. PHER-O2 is
under Phase II clinical trials and has oxygen-carrying capacity.

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation

PASADENA, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, supplies newly manufactured
PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2
for intravenous applications.

According to a Company spokesperson, should the pre-clinical trials for
intravenous use be successful, the Company would likely move toward a
development agreement with the potential of licensing PHER-O2 as part of a new
procedure. The procedure, which remains unnamed to protect the respective
company's proprietary material, could revolutionize a medical procedure that is
used every day through out the world.

Dr. Thomas C. Drees, Ph.D. - President and CEO - commented, "Management has
identified numerous applications for PHER-O2. Our most recent work as an ex-vivo
510(K) device for the transportation of transplant material is going well,
however we are keen to move into intravenous work, which has widespread
application. We feel this effort can move us swiftly toward this goal."

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation



CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)medancy@allwest.net




Copyright Business Wire 2008

PASADENA, Calif., Jan 08, 2008 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, supplies newly manufactured
PHER-O2 to a European Pharmaceutical Company. The group is evaluating PHER-O2
for intravenous applications.

According to a Company spokesperson, should the pre-clinical trials for
intravenous use be successful, the Company would likely move toward a
development agreement with the potential of licensing PHER-O2 as part of a new
procedure. The procedure, which remains unnamed to protect the respective
company's proprietary material, could revolutionize a medical procedure that is
used every day through out the world.

Dr. Thomas C. Drees, Ph.D. - President and CEO - commented, "Management has
identified numerous applications for PHER-O2. Our most recent work as an ex-vivo
510(K) device for the transportation of transplant material is going well,
however we are keen to move into intravenous work, which has widespread
application. We feel this effort can move us swiftly toward this goal."

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation



CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)medancy@allwest.net




Copyright Business Wire 2008

BLUE ISLAND, Ill., Dec 06, 2007 (BUSINESS WIRE) -- Apple Rush Company, Inc.
(Pink sheets:APRU) the producer of Organic 100% Juice beverages, has posted
their third quarter (3Q) 2007 financial results to its website at
www.applerush.com. Click on the 3rd Quarter 2007 under Apple Rush Financials to
view the data; 2nd Quarter financials are posted as well. The 3rd Quarter
results reflect approximately 24 days of consolidated financial results with the
acquisition of Garden/A1 Beverage on September 6, 2007. Both sets of financials
were also posted today on www.pinksheets.com . The symbol beside the stock is
now in the process of being changed to Limited Information and that will be
completed this afternoon. This will be upgraded to the Complete Information
Symbol once Pink Sheets completes their review of the additional qualifying
documents being submitted. Until recently Apple Rush was a subsidiary of
RushNet, Inc. (RSHN.PK).

Official, Fully-Disclosed Public Trading Begins Today in Apple Rush Stock
(APRU.PK)

According to Robert Corr, CEO of Apple Rush, "We are proud to officially begin
fully-disclosed public trading in Apple Rush stock today. We've achieved another
milestone by posting current financials for the Apple Rush Company to our
website as well as pinksheets.com, something we will be doing every quarter
going forward. We are looking forward to a strong 2008 for both Apple Rush and
Garden Beverage. We will keep shareholders updated on future developments."

About Apple Rush Company, Inc.

Apple Rush Company, Inc is a producer and marketer of Organic 100% Juice
beverages with nearly 40 Distributors throughout the U.S., and in foreign
markets, that sell the line to retailers. Centered in the burgeoning Organic
Foods category, 97% growth in the last five years, the lightly carbonated
Organic Apple Rush(TM) bottle line currently has six highly regarded flavors in
bottles that will also be available in 12 oz. cans in early 2008. Can volume is
expected to dwarf the bottle volume. Apple Rush also owns Garden/A1 Beverage in
Chicago, IL which distributes beverages to over 2000 accounts and whose sales
are growing 10% in 2007. More information is available at www.applerush.com

Disclaimer: The Company relies upon the Safe Harbor Laws of 1933, 1934 and 1995
for all public news releases. Statements, which are not historical facts, are
forward-looking statements. The company, through its management, makes
forward-looking public statements concerning its expected future operations,
performance and other developments. Such forward-looking statements are
necessarily estimates reflecting the company's best judgment based upon current
information and involve a number of risks and uncertainties, and there can be no
assurance that other factors will not affect the accuracy of such
forward-looking statements. It is impossible to identify all such factors.
Factors which could cause actual results to differ materially from those
estimated by the company include, but are not limited to, government regulation;
managing and maintaining growth; the effect of adverse publicity; litigation;
competition; and other factors which may be identified from time to time in the
company's public announcements.

SOURCE: Apple Rush Company, Inc.



CONTACT: Apple Rush Company, Inc.Robert Corr, 708-389-6625

"--1.00 bid" showing on scottrade; what does it mean?

Sanguine Selects Stuart J. Beebe to the Company's Management Advisory Team
Monday October 22, 6:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, selected Stuart J. Beebe to the Company’s management advisory team.

Mr. Beebe recently served as CEO/President of CNL Retirement Properties, Inc., one of the largest health care REITs in the country. Stuart was directly responsible for all strategic business initiatives, including development, acquisitions, and financing projects for the Company. Under his leadership, CNL Retirement Properties opportunistically acquired and developed, during a 32 month period, 280 properties located in 34 states, valued in excess of 3.5 billion. In October of 2006, he championed the sale of the company to Health Care Properties, the nation's largest healthcare REIT for $5.2 billion. Prior to heading CNL, he served as CFO of CNL Real Estate Group in Orlando for four years, after serving for 15 years as Senior VP for the Florida division of Lincoln Property Company.

Dr. Thomas C. Drees, Ph.D. – President and CEO, commented, “We are excited to have Stuart join our team. His experience in the areas of finance, business development, and acquisition negotiations enhances our ability to execute our previously discussed objectives. Our plan is to grow our company organically by completing the FDA approval of PHER-O2; while in parallel, acquiring a private company(s) whose expertise, management and earnings will enable us to move vigorously toward becoming a world class pharmaceutical company.”

Drees added, “During our development of PHER-02 as a blood alternative, we realized its incredible oxygen carrying capabilities. The total market potential for a FDA approved PHER-O2 is estimated at more than $7 billion in the U.S. alone. This would include both intravenous and ex-vivo applications. Currently we are working toward an ex-vivo 510(K) device FDA approval, with intravenous applications slated for the future. We believe that our product is far superior to any other product currently in the industry and represents a major breakthrough. Utilizing our team of experts, both domestically and within Europe, we look forward to add numerous products that work synergistically with our oxygen carrier.”

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company’s products, increased levels of competition for the Company, new products and technological changes, the Company’s dependence on third-party suppliers, and other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.



Contact:
For Sanguine Corporation
Michael Dancy, 801-746-3570 (Investor Relations)
medancy@allwest.net

--------------------------------------------------------------------------------
Source: Sanguine Corporation

Sanguine Corporation Presents a Message to Its Shareholders

Press Release Source: Sanguine Corporation

Tuesday September 25, 6:00 am ET


PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC - News) presents a message to its shareholders:
Dr Drees, Chairman and CEO of Sanguine stated, "Dear Sanguine Shareholders, let me take this opportunity to bring you current on the many programs that we have been working on during this last year. It has been a very important time for our company. Below you will find a brief overview on the product, PHER-O2, a synthetic red blood cell substitute and oxygen carrier; the current status for its FDA approval; significant changes to our management team; a direction moving our development stage company into a stronger and more diverse position; and what we see as a strong future for our shareholders.

In November of this last year, we completed our pre-Investigation New Device (pre-IND) meeting with the FDA. At this meeting, management presented phase II data and our proposed testing protocol as prepared by our previously announced program management team, including Dr. Shapiro from the University of Alberta in Edmonton. The data presented to the FDA related to Islet Cell transportation in a bath including emulsified PHER-O2. We have completed pre-animal trials as part of the Islet Cell transplant program. The FDA has classified the product as a device, which our management believes should significantly reduce the cost and timeframe of an approval. The FDA requested that follow up information related to a Master Drug File and a Method of Use be completed to support a 510(k) Medical Device application. Management expects this to be completed in the near future; however several important areas have been considered in preparing for the future of Sanguine.

Sanguine Corporation is a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion. The Company's current product, PHER-O2 is a second generation to the previously FDA approved Fluosol DA product. The Fluosol approval, led by Dr. Drees, was granted in Canada, the U.K., and Germany, Australia and New Zealand. The goal is to replace the current product used for transporting living tissue, known as UW (University of Wisconsin) solution (trade name: Viaspan(TM)). The availability of vital organs for transplant is severely limited, in part, because many of the systems most commonly used to preserve living tissue are believed to be based on 50-60 year old technologies and remain limited in their usefulness. As a result, organ banks do not have the true capability of storing organs for any significant length of time. The benefit of transporting the living tissue in an Oxygenated bath is believed to be significantly better than the current technology available. Once FDA approval is achieved, Sanguine believes that PHER-O2 will be used in a variety of ways, similar to Fluosol. It is the Company's goal to commence work with the many research programs that have contacted management related to adding PHER-O2 to their programs. These programs are for both intravenous use as well as outside the body similar to the current 510(k) Medical Device approach.

We look forward to talking about these new Collaboration & Product Development programs; however, they relate to new partnerships for sales and/or licensing of PHER-O2. The projects under consideration, and which are planned for collaborative effort, involve the transporting organs, new methods enabling the transport of organs at higher temperatures, further islet cell transportation, and surface wound treatment programs, metabolic imaging, and numerous other programs. Our goal is to complete the FDA 510(k)-device application, and then commence sales and licensing of PHER-O2. In parallel, programs using PHER-O2 internally will be completed. For intravenous use, PHER-O2 would be considered as a Biological agent.

To complete the above programs, we plan increase our management and advisory staff. We have completed the first phase of securing new management. We look forward to talking more about our new team in the future; however, we plan to rapidly move from a company doing research and development of PHER-O2 into a company with an FDA approved product ready for sales, and we are considering new opportunities such as potential acquisitions. When considering the possibility of acquisitions, our management team will ensure that the new company Sanguine is becoming has the ability to provide our employees and shareholders with long-term stability and opportunity.

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission."



Contact:
Sanguine Corporation,
Investor Relations:
Michael Dancy, 801-746-3570,
medancy@allwest.net
www.sanguine-corp.com.

Pepsi agrees to change as industry comes under increased criticism

NEW YORK - PepsiCo Inc. will spell out that its Aquafina bottled water is made with tap water, a concession to the growing environmental and political opposition to the bottled water industry.

According to Corporate Accountability International, a U.S. watchdog group, the world’s No. 2 beverage company will include the words “Public Water Source” on Aquafina labels.

“If this helps clarify the fact that the water originates from public sources, then it’s a reasonable thing to do,” said Michelle Naughton, a Pepsi-Cola North America spokeswoman.

Pepsi Chief Executive Indra Nooyi told Reuters earlier this week the company was considering such a move.

Pepsi’s Aquafina and Coca-Cola Co’s Dasani are both made from purified water sourced from public reservoirs, as opposed to Danone’s Evian or Nestle’s Poland Spring, so-called “spring waters,” shipped from specific locations the companies say have notably clean water.

Coca-Cola Co. told Reuters it will start posting online information about the quality control testing it performs on Dasani by the end of summer or early fall.

“Concerns about the bottled-water industry, and increasing corporate control of water, are growing across the country,” said Gigi Kellett, director of the “Think Outside the Bottle” campaign, which aims to encourage people to drink tap water.

San Francisco’s mayor banned city employees from using city funds to buy bottled water when tap water is available. Ann Arbor, Michigan passed a resolution banning commercially bottled water at city events and Salt Lake City, Utah asked department heads to eliminate bottled water.

Critics charge the bottled water industry adds plastic to landfills, uses too much energy by producing and shipping bottles across the world and undermines confidence in the safety and cleanliness of public water supplies, all while much of the world’s population is without access to clean water.

But industry observers said such opposition is unlikely to drain U.S. sales of bottled water, which reached 2.6 billion cases in 2006, according to Beverage Digest. The industry newsletter estimated that U.S. consumers spent about $15 billion on bottled water last year.

“Consumers have an affection for bottled water. It’s not an issue of taste or health, it’s about convenience,” the newsletter’s publisher, John Sicher, said. “Try walking up (New York City’s) Third Avenue on a hot day and getting a glass of tap water.”

Dave Kolpak, a portfolio manager at Victory Capital Management, said the environmental objections will have little impact on the bottom line for either Pepsi or Coke, though he admitted it could slow the market’s growth rate.

“Pepsi and Coke do not make a lot of profit” on bottled water, said Kolpak, adding that people may talk about the issue, but will likely continue buying some bottled water. Victory Capital owns about 3 million shares of PepsiCo among its $62 billion under management.

10,000 @.0004

PASADENA, Calif., May 08, 2007 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, in collaboration with its FDA
testing contractors and development team, recently added additional management
contractors to aid in moving the Company through the 510(k) device application
process. The new contractors are intended to aid in managing the 510(k) approval
and capitalization path.

The Company's product manufacturer, a well known pharmaceutical development
company located in Europe, is completing the chemistry, manufacturing and
controls (known as CMC) effort necessary to move PHER-O2 into a position where
large manufactured quantities are possible. This effort is also planned to
support the previously announced FDA requested task of preparing a Master Drug
File submission. According to a Company spokesperson, the Company has had
PHER-O2 prepared in small test-only quantities; however, it is now time to be
able to prepare PHER-O2 in large quantities.

Also as previously announced, the Sanguine team continues its effort in
preparing its protocol for the use of PHER-O2 in human whole organ transplant
tissue (Liver, Kidneys, Heart, Lung, etc.). Following the development of the
transport protocol and the submission of PHER-O2's Master Drug File submission,
the Company plans to file a Medical Device (510-K) application with the FDA.
Once complete for each organ, this designation will enable the sale of PHER-O2
as indicated for the transport of whole organs used in the $12 billion annual
organ and tissue transplantation market in the U.S.

Dr. Thomas C. Drees, Ph.D., President and CEO, commented, "We have been at the
forefront of synthetic blood innovation for the past decade, and continue to
make significant progress in the area. Recently, we received notification from
the FDA that PHER-O2 is (to be) classified as a medical device and not a drug,
which now avails us to apply for approval as such under a 510(k) filing instead
of a full Pre-Market Approval (PMA). We believe that this represents a great
opportunity for the Company inasmuch that we can look forward to a potentially
much shorter path to market."

Drees added, "During our development of PHER-O2 as a blood alternative, we
realized its incredible oxygen carrying capabilities. This led us to determine
that PHER-O2 has multiple prospective additional applications including:
transfusion recipients, heart attack and stroke victims and other applications,
with the intent of seeing that PHER-O2 is in every emergency room (ER) and
ambulance across the U.S. The total market potential for PHER-O2 is estimated at
more than $7 billion in the U.S. alone. We believe that our product is far
superior to any other product currently in the industry and represents a major
breakthrough. We are looking forward to making our FDA application and working
to take Sanguine to the next level."

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.

(financialwire.net via COMTEX) -- May 8, 2007 (FinancialWire) Sanguine Corp.
(OTCBB: SGNC), a bio-pharmaceutical company, in collaboration with its Food and
Drug Administration testing contractors and development team, recently added
additional management contractors to aid in moving the company through the 510k
device application process. The new contractors are intended to aid in managing
the 510k approval and capitalization path.

The company's product manufacturer, a pharmaceutical development company located
in Europe, is completing the chemistry, manufacturing, and controls effort
necessary to move PHER-O2 into a position where large manufactured quantities
are possible. This effort is also planned to support the FDA requested task of
preparing a master drug file submission. According to a company spokesperson,
Sanguine has had PHER-O2 prepared in small, test-only quantities.

The Sanguine team is also continuing its effort in preparing its protocol for
the use of PHER-O2 in human whole organ transplant tissue. Following the
development of the transport protocol and the submission of PHER-O2's master
drug file submission, the company plans to file a medical device application
with the FDA. Once complete for each organ, this designation will enable the
sale of PHER-O2 as indicated for the transport of whole organs used in the $12
billion annual organ and tissue transplantation market in the U.S.

Income Statement


http://finance.yahoo.com/q/is?s=sgnc.ob

What does this mean for us?


Massive G Media Positioned to Roll Up Hip Hop Media Assets
FRIDAY, MARCH 16, 2007 9:30 AM
- Market Wire


PENNSYLVANIA, PA, Mar 16, 2007 (MARKET WIRE via COMTEX) -- MASSIVE G MEDIA CORP. (a Nevada corp.) (PINKSHEETS: MSGM) The Company ratifies its previously completed re-organization of its Board of Directors & assets and liabilities pursuant to its previous business agreement with RHN Network Holdings (MD), Mecanismo Corp., Anton F. Muhammad (a/k/a Atonn Muhammad) and other ex-officers and directors.

The RHN Network Holdings "assets and liabilities" are now the subject of the senior secured lenders liens filed and accepted in Nevada and Maryland. Upon the Agents' complete inspection of the RHN assets and liabilities, distributed TV network audience and other disclosed properties, the senior lenders Agents did not find sufficient evidence that the RHN's audience was ever approximately 30 million viewers/subscribers as advertised and as previously stated in numerous press releases from October 2006 to the present. Certain of the Company's prior releases had announced that RHN was also to be seen by Cable subscribers in major metropolitan markets from the 1st Qtr 2007. The lenders found no evidence that this could be factual, possible or probable given the cash position of the Company pursuant to the Lenders' review. The Lenders were contacted by numerous other RHN Network Holdings' (MD) projects who've served to confirm the nature of RHN's business.

On March 5th, 2007 after notices were sent directly to the Company and its Counsel, the Company's majority shareholders defaulted on its senior debt interest payment resulting in the filed Liens against the Collateral. Anton Muhammad has since verbally alluded to an assets & liabilities cash purchase proposal to Mecanismo Corp., the entity that now owns and controls these assets and liabilities. So far no offer has been received by any party.

Giorgio Costonis, President & CEO of Massive G Media Corp. & RMD Entertainment, stated: "Our investors in RHN including RMD Entertainment (PINKSHEETS: RMDN) have in most cases successfully negotiated with the Creditors and we fully intend to implement revenue drivers and licensing opportunities for some of the RHN materials, but quite frankly RMD's production source has stronger and fresher content to combine with the more historical RHN archives. Hip Hop is about being fresh; everything has a shelf life."

The Company is called Massive G Media Corp. (PINKSHEETS: MSGM) effective 16th March 2007. There are 200,000,000 Shares Authorized, Common Issued and Outstanding 82,838,372.

www.massivegmedia.com

http://www.monkeybarlive.com/monkeybar.htm

Reverse Phone Number Lookup shows it belongs to:


Patricia Alpizar
4059 47th St
Chicago, IL 60632
Phone: 773-247-8626

Sanguine Receives FDA Meeting Minutes to Define PHER-O2 Regulatory Path
TUESDAY, JANUARY 23, 2007 6:00 AM

PASADENA, Calif., Jan 23, 2007 (BUSINESS WIRE) -- Sanguine Corporation (SGNC) , a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, received its meeting minutes letter from the FDA related to the Company's regulatory approval path. The Company is pleased to announce that it is complete with its animal testing program and is preparing to complete the manufacturing process to support PHER-O2's Master Drug File (MDF) submission to the FDA. Information related to Drug Master Files may be found at: http://www.fda.gov/cder/guidance/dmf.htm.

Furthermore, the Sanguine team is preparing its protocol for the use of PHER-O2 in human whole organ transplant tissue (Liver, Kidneys, Heart, Lung, etc...) as detailed by the Company's meeting minutes. Following the development of the transport protocol and the submission of PHER-O2's MDF, the Company plans to file a Medical Device 510(k) application. Once complete for each organ, this designation will enable the sale of PHER-O2 as indicated for the transport of whole organs used in the 12 billion-dollar annual organ and tissue transplantation market in the U.S.

Dr. Thomas C. Drees, Ph.D. - President and CEO added, "Our medical advisory team is to be commended related to the effort necessary to support the FDA meeting. We are excited to finally have a clear path toward our 510(k) application and potential approval for product sales. Although we will not know the final time-line for the submission until we have completed the manufacturing study and the human protocol, our team is in agreement that the total process should be substantially shorter than originally planned when considering intravenous use of PHER-O2. We look forward to announcing further updates, as they become available."

For information related to the Sanguine Corporation, contact Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation

For Sanguine Corporation
Michael Dancy, 801-746-3570 (Investor Relations)
e-mail: medancy@allwest.net
www.sanguine-corp.com


Copyright Business Wire 2007

CORRECTING and REPLACING Sanguine Meets with FDA To Define PHER-O2 Regulatory Path

PASADENA, Calif., Dec 06, 2006 (BUSINESS WIRE) -- Second graph, first sentence

of release dated Dec. 5, 2006 should read: PIRIBO, a well known BioPharma

Industry analyst, reported that the annual organ and tissue transplantation

market in the U.S. was estimated at $11.7 billion in 2005 and is expected to

rise at an average annual growth rate (AAGR) of 5.2% to $15.1 billion by 2010

(sted PRIBO, a well known BioPharma Industry analyst, reported that the annual

organ and tissue transplantation market in the U.S. was estimated at $11.7

billion in 2005 and is expected to rise at an average annual growth rate (AAGR)

of 5.2% to $15.1 billion by 2010.)


The corrected release reads:


SANGUINE MEETS WITH FDA TO DEFINE PHER-O2 REGULATORY PATH


Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company

focused on the development of an oxygen-carrying synthetic substitute for human

red blood cells and numerous other areas requiring oxygen profusion, in

collaboration with its FDA testing contractors and development team, met with

the FDA to discuss the Company's regulatory path. The Company believes that its

product, PHER-O2, is appropriately suited for whole organ (pancreas and kidney),

preservation for transplantation.


PIRIBO, a well known BioPharma Industry analyst, reported that the annual organ

and tissue transplantation market in the U.S. was estimated at $11.7 billion in

2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to

$15.1 billion by 2010. The transplantation market was estimated at just under $5

billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector

is small bowel (intestine) transplantation. Kidney and liver transplantation

will account for 78% of the total in 2005. The U.S. tissue transplantation

market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of

5.5%, to $8.9 billion in 2010. A copy of the report may be found at:

www.piribo.com/publications/biotechnology/organ_tissue_

transplantation_alternatives.html (Due to its length, this URL may need to be

copied/pasted into your Internet browser's address field. Remove the extra space

if one exists.)


Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely

excited to have finally met with the FDA related to our testing program. As I

have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell

preservation in treating diabetes (the fastest growing disease in the world) is

particularly attractive because the product is used ex-vivo (outside the body),

which should simplify the regulatory process. We are most interested in

generating a device indication that presumably would be the most expedient route

toward our ability to market PHER-O2. As indicated by numerous BioPharma

sources, the transplantation market is substantially large. Our plan is to use

PHER-O2 in conjunction with other transplantation transport materials to provide

an oxygenated environment to aid in the longevity of whole organs. We look

forward to having our development team continue its work with the FDA to

finalize the most appropriate and direct regulatory path. We feel the meeting

with the FDA was quite successful."


For information related to the Sanguine Corporation, contact Investor Relations:

Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:

www.sanguine-corp.com.


Forward-looking statements in this release are made pursuant to the "safe

harbor" provisions of the Private Securities Litigation Reform Act of 1995.

Investors are cautioned that such forward-looking statements involve risks and

uncertainties, including without limitation, continued acceptance of the

Company's products, increased levels of competition for the Company, new

products and technological changes, the Company's dependence on third-party

suppliers, and other risks detailed from time to time in the Company's periodic

reports filed with the Securities and Exchange Commission.


SOURCE: Sanguine Corporation




CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy@allwest.netwww.sanguine-corp.com






Copyright Business Wire 2006

PASADENA, Calif., Dec 05, 2006 (BUSINESS WIRE) -- Sanguine Corporation (OTC
Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development
of an oxygen-carrying synthetic substitute for human red blood cells and
numerous other areas requiring oxygen profusion, in collaboration with its FDA
testing contractors and development team, met with the FDA to discuss the
Company's regulatory path. The Company believes that its product, PHER-O2, is
appropriately suited for whole organ (pancreas and kidney), preservation for
transplantation.

PRIBO, a well known BioPharma Industry analyst, reported that the annual organ
and tissue transplantation market in the U.S. was estimated at $11.7 billion in
2005 and is expected to rise at an average annual growth rate (AAGR) of 5.2% to
$15.1 billion by 2010. The transplantation market was estimated at just under $5
billion in 2005 and is expanding at an AAGR of 4.8%. The fastest growing sector
is small bowel (intestine) transplantation. Kidney and liver transplantation
will account for 78% of the total in 2005. The U.S. tissue transplantation
market totaled about $6.8 billion in 2005. It is projected to grow at an AAGR of
5.5%, to $8.9 billion in 2010. A copy of the report may be found at:
www.piribo.com/publications/biotechnology/organ_tissue_
transplantation_alternatives.html (Due to its length, this URL may need to be
copied/pasted into your Internet browser's address field. Remove the extra space
if one exists.)

Dr. Thomas C. Drees, Ph.D. - President and CEO remarked, "We are extremely
excited to have finally met with the FDA related to our testing program. As I
have mentioned previously, the use of PHER-O2 for pancreas and/or islet cell
preservation in treating diabetes (the fastest growing disease in the world) is
particularly attractive because the product is used ex-vivo (outside the body),
which should simplify the regulatory process. We are most interested in
generating a device indication that presumably would be the most expedient route
toward our ability to market PHER-O2. As indicated by numerous BioPharma
sources, the transplantation market is substantially large. Our plan is to use
PHER-O2 in conjunction with other transplantation transport materials to provide
an oxygenated environment to aid in the longevity of whole organs. We look
forward to having our development team continue its work with the FDA to
finalize the most appropriate and direct regulatory path. We feel the meeting
with the FDA was quite successful."

For information related to the Sanguine Corporation, contact Investor Relations:
Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit:
www.sanguine-corp.com.

Forward-looking statements in this release are made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements involve risks and
uncertainties, including without limitation, continued acceptance of the
Company's products, increased levels of competition for the Company, new
products and technological changes, the Company's dependence on third-party
suppliers, and other risks detailed from time to time in the Company's periodic
reports filed with the Securities and Exchange Commission.

SOURCE: Sanguine Corporation



CONTACT: For Sanguine CorporationMichael Dancy, 801-746-3570 (Investor Relations)e-mail: medancy@allwest.netwww.sanguine-corp.com




Copyright Business Wire 2006

read this Letter on Sanguine's site

http://www.sanguine-corp.com/images/Shareholder%20Let%20Final.pdf

RMD Entertainment Group JV Secures Exclusive TV "Hip Hop Hall of Fame" Event Inducting "Tupac Shakur" & "Biggie Smalls"

PHILADELPHIA, PA, Nov 28, 2006 (MARKET WIRE via COMTEX) -- RMD Entertainment

Group (PINKSHEETS: RMDG), in conjunction with co-executive producer Global Media

LLC, announced today exclusively in an interview on MN1.com (www.mn1.com) that

the Hip Hop Hall of Fame Awards, Induction Ceremony and Concert (the "Event")

will take place at the legendary Apollo Theater, New York, NY. The date of the

Event will be announced through all major TV media outlets.


The two-hour special Event will be produced by Global Media LLC and ION Media

Networks pursuant to the mutual satisfaction of the Licensor and Licensee. ION

Media Networks, Inc. (formerly Paxson Communications Corporation) is a network

television broadcasting company which owns and operates the largest broadcast

television station group in the United States, as measured by the number of

television households in the markets the Company's stations serve. ION provides

network programming seven days per week, 24 hours per day, through its broadcast

television station group and pursuant to distribution arrangements with cable

and satellite distribution systems.


Co-executive producers Global Media LLC and RMD Entertainment Group have further

agreed that RHN.TV (Real Hip Hop Matrix) (RMHX) will distribute the Event

thereafter through U.S. cable, satellite and internet networks.


Giorgio Costonis, CEO of RMD Entertainment Group, stated, "We are delighted with

our role to executive produce this spectacular star-studded Event with such

venerable partners. RMDG now adds these shared revenue drivers along with our

partners including, but not limited to, advertising, branding, merchandise

sales, DVD sales, Pay-Per-View sales, Video-on-Demand, and MOTV subscriptions,

all of which we will channel with highly exclusive and sought-after hip-hop

content."


Global Media LLC (Owner & Operator of Hip Hop Hall of Fame) CEO James T.

Thompson stated, "Hip Hop Hall of Fame has once again become an astonishingly

hot property. The advent of Tupac Shakur and Biggie Smalls being inducted into

the Hip Hop Hall of Fame a decade after their deaths only serves to make the

Event all the more exciting. Hip-hop culture is a 'Madison Avenue' sweetheart as

is evidenced everywhere in the popular media. Our Joint Venture organization

will be booking major advertising campaigns with several well-known brand names

and a major credit card vendor for this special Event. The talent roster for the

Event is a who's who of hip-hop entertainment. Event details, hosts, presenters,

performances and Event DJs, along with special appearances, will be released in

an upcoming public announcement. This is all very exciting."


Instrumental in orchestrating these parties together and planting the seeds of

future content distribution and advertising sales, Kendrick Lesane, COO of RHMX

+ RHN.TV (www.realhiphopmatrix.com) and first cousin to the late Tupac Shakur,

stated, "We believe that this example of special Event programming is a view

into a wave of future collaborations between cable, satellite and IP delivery in

a highly stylized, branded format. RHN.TV will use this Event product and others

like it to break RHN.TV into new U.S. markets and win deeper subscriber loyalty

through stylized branding, programming and advertising in larger metropolitan

markets. RHMX will be re-branding and converting Event content for certain new

Customers who market innovative portable audio and video players and for mobile

phones that play MP3 and MP4 files. Our bet is that a large portion of the

world's content subscribers will be regularly watching TV broadcasts on mobile

devices within two years. This will open up lucrative markets for both content

producers and network distributors. It's all good."


About Real Hip Hop Matrix + RHN.TV


Real Hip Hop Matrix + RHN.TV is the first 24-hour cable network dedicated

exclusively to hip-hop lifestyle and culture. RHN.TV currently broadcasts to

approximately 22 million U.S. households. The Washington, D.C.-based network has

a regular programming schedule devoted almost entirely to the hip-hop

marketplace with a targeted selection of programming centered on the foundation

of hip-hop's core elements: Deejaying, Emceeing, Break dancing and Graffiti.


Target Audience: 18-34 demographic, in both urban and suburban markets; certain

programming is targeted toward the 12-24 audience.


Distribution: RHN.TV can be seen in over 22 million U.S. households through Dish

Network (Channel 9407), Comcast in Denver (Channel 55) and in LA on Adelphia

through a programming agreement with CoLours TV. RHN.TV has been on air in the

Washington, D.C. market through MHz since July 1, 2006. RHN.TV's distribution

through OlympuSat provides 24-hour access to 15 million homes in 2005 growing to

approximately 43 million homes by 2008. OlympuSat provides distribution through

a multi-content agreement with Dish Network, Direct TV and the top 10 major

cable channels. IP distribution of RHN.TV is offered through a partnership with

ROO Group Inc.


Enjoy our web presence: www.rhn.tv, www.realhiphopmatrix.com,

www.realhiphopmatrix.net


About ION Media Networks


ION Media Networks, Inc. owns and operates the nation's largest broadcast

television station group and the i network, reaching over 92 million U.S.

television households via its nationwide broadcast television, cable and

satellite distribution systems. For more information, please visit

www.ionmedia.tv. About RMD Entertainment Group


RMD Entertainment is a cutting-edge entertainment company that is primarily

focused on the development and international marketing of 'hip-hop' music,

including compact discs, digital downloads, and personal 'ring tones' for mobile

phone customers, as well as other 'hip-hop' lifestyle products. The Company has

also created MOTV, the ability to stream video content to mobile devices,

including cell phones and PDA's. The Company currently possesses an impressive

hip-hop music catalogue, which it distributes through Bungalo Records and

Universal Music Group (a subsidiary of Vivendi Universal in North America) and

in Europe through the Pickwick Group Ltd. of London.


www.rmd-entertainment.com/


Forward-looking statements in this news release relating to the Company's

expectations regarding RMDG, RHMX, ION demand and pricing are made pursuant to

the "safe harbor" provisions of the United States Private Securities Litigation

Reform Act of 1995. When used herein, words such as "expect" and similar

expressions are intended to identify forward-looking statements. Forward-looking

statements are based on assumptions made by and information available to RMDG

Entertainment Group ION Media Networks, Inc and Real Hip Hop Matrix Corp.

Investors are cautioned that such forward-looking statements involve risks and

uncertainties. Important factors that could cause actual results to differ

materially from those expressed or implied by such forward looking statements

include, without limitation, the future demand for, and sales volumes of, the

Company's products, future production volumes, efficiencies and operating cots,

increases or decreases in the prices of the Company's products, the Company's

future stability and growth prospects, the Company's future profitability and

capital needs, including capital expenditures, and the outlook for and other

future developments in the Company's affairs or in the industries in which the

Company participates and factors detailed from time to time in the Company's

periodic reports filed with the United States Securities and Exchange

Commission, and other regulatory authorities. The Company has no intention or

obligation to update or revise any forward-looking statements, whether as a

result of new information, future events or otherwise.







CONTACT:


Real Hip-Hop Matrix Corp + RHN.TV


Atonn Muhammad


202-434 8374





Public Relations:


Clarke & Associates


Priscilla Clarke


202-723 2200

Sanguine Corporation CEO Featured in Exclusive Interview With WallSt.net
THURSDAY, OCTOBER 26, 2006 7:00 AM
- PR Newswire

SGNC
0.10 n/a



NEW YORK, Oct 26, 2006 /PRNewswire via COMTEX/ -- On October 24, Dr. Thomas Dress, Chief Executive Officer for Sanguine Corporation (SGNC) updated the investment community in an exclusive interview with www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.

To hear the interview in its entirety, visit www.wallst.net , and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.

About Sanguine Corporation:

Sanguine Corporation is a public company based in Pasadena, California, whose primary focus is the development of PHER-O2, a perfluorocarbon (PFC) emulsion with oxygen carrying properties that has immediate applications as an intravenous supplement to red blood cell function. For more information, please visit the company website at www.sanguine-corp.com .

About WallSt.net:

www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The website is a leading provider of financial news, media, tools and community-driven applications for investors. www.wallst.net offers visitors free membership to its in-depth executive interviews, exclusive editorial content, breaking news, and several proprietary applications. In addition to its website, WallStreet Direct organizes investor conferences, publishes a newspaper, and provides multimedia advertising solutions to small and mid-sized publicly traded companies. We are expecting to receive two hundred eighty dollars from Sanguine Corporation for the dissemination of this press release. For a complete list of our advertisers, and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp .


SOURCE WallStreet Direct, Inc.

Nick Iyer of Digital Wall Street, Inc., +1-800-4-WALL-ST


http://www.wallst.net


Copyright (C) 2006 PR Newswire. All rights reserved

Interesting:

http://www.nytimes.com/2006/10/27/business/27sec.html?_r=1&ref=business&oref=slogin

Posted by: hayden proffit
In reply to: None


SEC being investigated- from another board - some good news finally on naked shorts
http://www.thesanitycheck.com/BobsSanityCheckBlog/tabid/56/EntryID/495/Default.aspx

Posted by: gamood
In reply to: None

OT....Cal-Bay International's Review of NOBO List Leads to Mandatory Certificate Exchange of Common and Class B Shares

CARLSBAD, Calif.--(BUSINESS WIRE)--Cal-Bay International, Inc. (OTCBB:CBAY) announced after diligent review of the NOBO (notice of beneficial ownership) list the company is today instructing the company’s transfer to notify in writing all shareholders who own Cal-Bay common and Preferred “B” shares of the mandatory certificate exchange and the necessary procedures along with the deadlines to effect the exchange.

Cal-Bay’s Board of Directors announced the mandatory exchange after careful review of the NOBO list and in conjunction with the recent “Short List” publication by NASDAQ of Cal-Bay’s short sell position.

Cal-Bay’s Board of Directors commented, “this is an expensive way to try and combat the obvious short position, but in the interest of the Shareholders, Investors and the Company it became a necessary decision. The company will not disclose the terms of the exchange publicly as authentic holders of the company’s stock will be notified in writing by the transfer agent along with the exchange procedures and deadlines”.

www.calbayinternational.com

www.cobshomes.com

www.tlcosoftware.com

I have owned shares in this company Since 2004. I'm waiting to see if it makes head way. there are positives in it. The FDA plan is going ahead and they have responded to my emails. the application of the product in keeping islet cells alive for transplant is very important in the fight against diabetes. if this company can suceed in the FDA trails it will push this company through the roof.

http://www.scifi.com/sfw/issue235/labnotes.html

Posted on: Tuesday, 7 February 2006, 06:00 CST
Sanguine Evaluates a New Science Approach to Use PHER-O2 in Conjunction With Type 2 Diabetes Therapies
Sanguine Corp. (OTCBB: SGNC), a bio-pharmaceutical company focused on the development of oxygen-carrying synthetic substitutes for human red blood cells and numerous other areas requiring oxygen perfusion, was presented a new scientific approach by an international medical group whereby PHER-O2 would be used to increase oxygenation to the small vessels that supply blood to critical areas of the body affected by Type 2 diabetes. Dr. Robert Kwun, a board-certified surgeon, is evaluating the science for the Sanguine medical team.

Kwun remarked, "The Sanguine product, PHER-O2, has long been viewed by us as a blood substitute. However, when considering the oxygen-carrying capacity associated with the product's predecessor, FDA-approved Fluosol, it's reasonable that PHER-O2 could be beneficial to many medical situations where increased oxygen into the microvascular system is desired. In addition to the Edmonton protocol and PHER-O2 work, which are for type 1 diabetics, it follows that efforts to evaluate science, which could aid type 2 diabetics directly, compliments the company's expanded business direction involving diabetes therapies. I look forward to evaluating this science to determine if PHER-O2 can play a role."

Dr. Thomas C. Drees, Ph.D., president and CEO, added, "The worldwide market for diabetic therapies, both type 1 and type 2, is huge. According to industry sources, the diabetes market is believed to top 10 billion dollars annually and growing. We are anxious and happy to consider any science where PHER-O2 may play a beneficial role in diabetic medical therapies. Our team looks forward to Dr. Kwun's findings."

For information related to the Sanguine Corp., contact Investor Relations: Michael Dancy, 801-746-3570, e-mail: medancy@allwest.net, or visit: www.sanguine-corp.com.

ANH Bulletin
Volume 9, No. 87, September/October 2006

Quarterly Literature Update

The following contains the quarterly summary of peer-reviewed publications related “exclusively” to ANH for the months of July to September 2006, (and a few publications missed during the prior quarter) taken from the National Library of Medicine databases. My commentary (italics) may be added to reports of special import. NLIM now lists abstracts before they are formally published, as “Epubs.” For simplicity, Epubs are listed separately.

Bennett J et al: Acute normovolemic hemodilution in moderate blood loss surgery: a randomized controlled trial. Transfusion, Volume 46, pages 1097-1103. (PMID: 16836555) Patients undergoing elective hip surgery wee randomized to either ANH or a standard transfusion group. Blood transfusion requirements did not differ significantly between groups. However, infective complications were lower in the ANH group.

Cabrales P et al: Blood viscosity maintains microvascular conditions during normovolemic anemia independent of blood oxygen-carrying capacity. American Journal of Physiology Heart and Circulatory Physiology, Volume 291, pages H581-590. (PMID: 16517943) Another hamster window microcirculation study from this prolific group in which effects of ANH on viscosity and oxygen delivery were studied. In this study, decreased microcirculatory conditions associated with ANH were secondary to decreased viscosity, not decreased oxygen delivery.

Epstein NE et al: Impact of intraoperative normovolemic hemodilution on transfusion requirements for 68 patients undergoing lumbar laminectomies with instrumented posterolateral fusion. Spine, Volume 31, pages 2227-2230 with discussion on page 2231. (PMID: 16946658) The effect of ANH on allogeneic transfusion was studied in patients undergoing extensive spine surgery. The majority of patients required no allogeneic blood, although this study is seriously flawed from a methodological standpoint.

Farina JA et al: Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats. Microsurgery, Volume 26, pages 456-464. (PMID: 16924631) A rodent study that compared ANH with albumen or dextran with fractionated heparin in reducing thrombus formation in venous anastomosis. ANH with albumen was the most effective antithrombotic agent.

Han SH et al: The effect of esmolol-induced controlled hypotension in combination with acute normovolemic hemodilution on cerebral oxygenation. Acta Anaesthesiologica Scandinavica, Volume 50, pages 863-868. (PMID: 16879470) The effect of ANH and controlled hypotension on cerebral oximetry was studied in patients undergoing orthopedic surgery. Controlled hypotension plus ANH was associated with lower regional oxygen saturation indices compared to ANH alone.

Huang Y et al: PEGylated albumin-heme as an oxygen-carrying plasma expander: Exchange transfusion into acute anemia rat model. Biomaterials, Volume 27, pages 4477-4483. (PMID: 16678256) A study in rats using ANH to simulate a hemorrhagic state, examined the effect of a novel PEgylated albumen heme on various parameters of oxygen transport. The PEGylated solution functioned as an effective oxygen-carrying plasma expander.

Jabbour N et al: Impact of a transfusion-free program on non-Jehovah's Witness patients undergoing liver transplantation. Archives of Surgery, Volume 141, pages 913-917. (PMID: 17001788) Since the inception of the transfusion-free liver transplantation program at USC – LA, 239 orthotopic liver transplants were performed. Compared to an earlier control group, the transfusion-free program has reduced allogeneic transfusion rates.

Loubser PG: Needleless adaptation to blood collection bags used for acute normovolemic hemodilution. Anesthesia Analgesia, Volume 103, pages 491-492. (PMID: 1686144) Letter describing a modification of blood collection bags used for ANH.

Mathru M et al: Splanchnic oxygen consumption is impaired during severe acute normovolemic anemia in anesthetized humans. Anesthesiology, Volume 105, pages 37-44. (PMID:16809992) They induced ANH to a Hb of 6 g/dl, in patients undergoing spine or abdominal surgery, studying several parameters of splanchnic oxygen delivery and consumption. Splanchnic oxygen consumption was impaired and oxygen delivery decreased, suggesting that the risk to the GI tract during ANH is substantial.

Morariu AM et al: Acute isovolemic hemodilution triggers proinflammatory and procoagulatory endothelial activation in vital organs: role of erythrocyte aggregation. Microcirculation, Volume 13, pages 397-409. (PMID: 16815825) A porcine study examining erythrocyte aggregation and endothelial activation during ANH. Erythrocyte aggregation was reduced during ANH. The findings suggest an endothelium-dependent thrombogenic response may occur in the microcirculation during ANH.

Ramnarine IR et al: Autologous blood transfusion for cardiopulmonary bypass: effects of storage conditions on platelet function. Journal of Cardiothoracic and Vascular Anesthesia, Volume 20, pages 541-547. (PMID: 16884986) Platelet function (impedance aggregometry) of ANH blood stored in citrate or heparinized blood bags at room temperature was studied in 27 patients undergoing CABG surgery. Platelet function was reduced by storage in both agents, although more with heparin. Even after reinfusion, platelet function in vivo was reduced. The authors conclude that ANH whole blood should not be stored in citrate. Scharbert et al, Anesth Analg, Volume 102, pages 1280-4, 2006, reported that platelets stored at room temperature were associated with marked inhibition of platelet aggregation. This effect was absent when platelets were stored near 37oC. So, are Ramnarine’s findings secondary to temperature, citrate, heparin or both?

Ruttmann TG et al: The haemodilution enhanced onset of coagulation as measured by the thrombelastogram is transient. European Journal of Anaesthesiology, Volume 23, pages 574-579. (PMID: 16507197) Volunteers were subjected to hemodilution by rapidly infusing crystalloid. TEG showed faster onset of coagulation, while antithrombin levels decreased.

Shander A et al: The long and winding road of acute normovolemic hemodilution. Transfusion, Volume 46, pages 1075-9. (PMID: 16836551) An editorial comment on the study by Bennett et al, above, in the same Journal.

Sharma V et al: Evaluation of Epsilon amino-caproic acid (EACA) and autologous blood as blood conservation strategies in patients undergoing cardiac surgery. Heart, Lung and Circulation, Volume 15, 261-265. (PMID: 16698318) They compared two groups of patients undergoing cardiac surgery. ANH was performed in one group while EACA was used in the other. No difference was found between groups with respect to allogeneic transfusion. However, this study is seriously flawed from a methodological standpoint.

Verdin-Vasquez RC et al : Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artificial Cells Blood Substitutes Immobilization Biotechnology, Volume 34, pages 433-454. (PMID: 16818416) The PFC perftoran was used in conjunction with ANH in 30 patients undergoing cardiac surgery. Compared to controls, the Perftoran patients manifested a higher PaO2 and required less allogeneic blood

Dear Manny,

The product PHER-O2 is in its pre IND phase with Cardinal Health and the
University of Alberta. The company has heard from the FDA and the FDA has
determined that the trial approach is as a device, which I understand from
Cardinal is a very good thing.

Best regards
Michael Dancy

Sym = wdcv @.001

Holding only 1.6 mil shares.

The capital gains tax rate is currently 15% for an elapsed time between purchase and sale of more than one year, and your normal tax rate for an elapsed time of 1 year or less. Captial Gains can be for any asset, common assets are stocks, bonds, or real estate.

If you sold all your shares then stop posting on this board. you are not going to succeed with your bashing. you will not get my shares or no one else's on this board. we are looking forward and all we see is an upward trend.

this is just capital gain you basher. as everyone knows on this board that the capital gain tax is not 100% or 50%. take your spin somewhere else.

True and like most companies not all projects are public knowlege. you would not want the competition what you are up to and steal your idea. let's try not to be scare off into a mistake that we will regret. like selling when we should have held on tight.

you have been negative on all your post on this board and others that I have visited that you are on. please keep your negative thoughts to yourself. If we want to hold on to our stocks and wait; it is our choice and our right.

I have received this email from Scottrade:

From: "Scottrade Customer Support" <support@scottrade.com>
To: <mr.encar@verizon.net>
Sent: Wednesday, August 23, 2006 10:53 AM
Subject: RE: Technical



Dear Investor:

Thank you for your email. We have checked DTC and Bloomberg regarding
the announcement of the dividend in your message. The below hyperlink
details the announcement. Neither DTC or Bloomberg have a pay date.
While the company has announced the dividend and scheduled a date, an
announcement is not equal to issuing the shares.

http://money.cnn.com/services/tickerheadlines/mw/06134989.htm

Please let us know if you have any further questions.

Sincerely,

Steve B.
Scottrade Inc.
National Service Center
http://www.scottrade.com

I have Emailed Giorgio Costonis But have not heard from him.